Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySun, 09 Jun 2024 09:54:08 +0200Tue, 02 Apr 2024 17:24:00 +0200Human medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/celdoxome-pegylated-liposomalHuman medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/celdoxome-pegylated-liposomalTue, 02 Apr 2024 17:24:00 +0200Human medicineCeldoxome pegylated liposomal : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5330-en.pdfCeldoxome pegylated liposomal : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5330-en.pdfTue, 02 Apr 2024 17:20:00 +0200Human medicine